Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Market Cap	24.99B +189.5%
Revenue (ttm)	3.96B -40.8%
Net Income	513.69M -75.8%
EPS	2.21 -75.7%
Shares Out	576.03M
PE Ratio	19.59
Forward PE	n/a
Dividend	5.69 (13.57%)
Ex-Dividend Date	Jul 31, 2025

Volume	279,914
Average Volume	567,458
Open	42.00
Previous Close	42.00
Day's Range	41.42 - 43.50
52-Week Range	32.62 - 67.30
Beta	-0.05
RSI	49.26
Earnings Date	Mar 30, 2026

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 4,861
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6887

Financial Performance

In 2024, Sunshine Lake Pharma's revenue was 3.72 billion, a decrease of -40.84% compared to the previous year's 6.29 billion. Earnings were 482.71 million, a decrease of -75.78%.

Financial numbers in CNY